Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CRUISER: Concurrent Durvalumab with CRT in Stage III NSCLC
NCT04982549Phase 2Unknown
- Sponsor
- Shandong Cancer Hospital
- Start
- Jan 2021
- Primary completion
- Dec 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Incidence of Grade >=3 Immune-mediated Adverse Events up to 4 years. Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04982549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982549.